BRAF L597K mutation: an opportunity to treat

The outcomes of patients with metastatic melanoma (MM) have significantly improved after the introduction BRAF-specific inhibitors. Herein is reported a patient MM and non-V600-BRAF mutation who responded to iBRAF/iMEK therapy. In July 2014, 63-year-old man presented 4.1mm-thick V600E-BRAF wild type on back. Metastases were identified in one sentinel node two 11 subsequently excised lymph nodes, no signs distant disease. September 2017, lung metastasis was observed pembrolizumab started. Progressive disease apparent at cycle 10 therapy switched ipilimumab. After four cycles, an asymmetric response observed. November next generation sequencing genomic profiling disclosed rare L597K-BRAF vemurafenib plus cobimetinib initiated January 2018. Seven days treatment start, remarkable clinical improvement April 2018, achieved partial response, which sustained until October Cases mutations responding been over last years. To best our knowledge, this first case reporting combined harboring L597K mutation.